tirzepatide discontinuation Causes and consequences of of GLP1RAs or How to wean off tirzepatide:

New patients: select Month 1. Our clinical team will assess your eligibility and guide your dosing plan throughout the program

Dose reduction was required in 12.5% of patients, mostly owing to gastrointestinal symptoms, and discontinuation for any reason occurred in 5.5%

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

This article explores medical weight loss options, focusing on semaglutide and its role in achieving weight loss goals